Evidence map›Paper›PMID 35748297›Full record

ArticleDevelopment (Cambridge, England)2022

Generation of functional human oligodendrocytes from dermal fibroblasts by direct lineage conversion.

Koji Tanabe, Hiroko Nobuta, Nan Yang, Cheen Euong Ang, Philip Huie, Sacha Jordan, Michael C Oldham, David H Rowitch, Marius Wernig

Open access · hybridAbstract read
In one paragraph

Article in Development (Cambridge, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Remyelination in the Central Nervous System.Cold Spring Harbor perspectives in biology · 2024
    Review
  6. Review
  7. Article
  8. The epigenetic landscape of oligodendrocyte lineage cells.Annals of the New York Academy of Sciences · 2023
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Koji TanabeI Peace, Inc, Palo Alto, CA 94303, USA.
Hiroko NobutaEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0003-1410-2086
Nan YangInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Cheen Euong AngInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-9050-6122
Philip HuieDepartment of Surgical Pathology, Stanford Health Care, Palo Alto, CA 94305, USA.
Sacha JordanCenter for Advanced Biotechnology and Medicine, Rutgers University, Piscataway, NJ 08854, USA.
Michael C OldhamEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA 94143, USA.
David H RowitchEli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA 94143, USA.
Marius WernigInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-5309-515X
Stanford University · USUniversity of California, San Francisco · USRutgers, The State University of New Jersey · USStanford Health Care · US

Funding

Decoding the molecular basis of cellular identity in the human brainR01MH113896 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OLDHAM, MICHAEL CLARK · 2018 to 2022
$2.0M
Department of HealthMedical Research Council MC_PC_17230NIMH NIH HHS R01 MH113896
6 · The paper itself

Abstract

Oligodendrocytes, the myelinating cells of the central nervous system, possess great potential for disease modeling and cell transplantation-based therapies for leukodystrophies. However, caveats to oligodendrocyte differentiation protocols ( Ehrlich et al., 2017; Wang et al., 2013; Douvaras and Fossati, 2015) from human embryonic stem and induced pluripotent stem cells (iPSCs), which include slow and inefficient differentiation, and tumorigenic potential of contaminating undifferentiated pluripotent cells, are major bottlenecks towards their translational utility. Here, we report the rapid generation of human oligodendrocytes by direct lineage conversion of human dermal fibroblasts (HDFs). We show that the combination of the four transcription factors OLIG2, SOX10, ASCL1 and NKX2.2 is sufficient to convert HDFs to induced oligodendrocyte precursor cells (iOPCs). iOPCs resemble human primary and iPSC-derived OPCs based on morphology and transcriptomic analysis. Importantly, iOPCs can differentiate into mature myelinating oligodendrocytes in vitro and in vivo. Finally, iOPCs derived from patients with Pelizaeus Merzbacher disease, a hypomyelinating leukodystrophy caused by mutations in the proteolipid protein 1 (PLP1) gene, showed increased cell death compared with iOPCs from healthy donors. Thus, human iOPCs generated by direct lineage conversion represent an attractive new source for human cell-based disease models and potentially myelinating cell grafts.

Indexed as

Induced Pluripotent Stem CellsPelizaeus-Merzbacher DiseaseCell DifferentiationFibroblastsHumansOligodendrogliaDirect lineage conversionFibroblastsHumanLeukodystrophyMyelinationOligodendrocyte

Identifiers

PMID35748297
PMCPMC9357374
OpenAlexW4283392478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.